An effective and safe protocol involving zidovudine and caesarean section to reduce vertical transmission of HIV-1 infection

AIDS

Volumn 14, Issue 18, 2000, Pages 2903-2911

  Grosch Wörner, Llse ^a   Schäfer, Axel ^a   Obladen, Michael ^a   Maier, Rolf F ^a   Seel, Karen ^a   Feiterna Sperling, Cornelia ^a   Weigel, Ralf ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Caesarean section; Epidemiology; Prophylaxis; Vertical transmission; Zidovudine

Indexed keywords

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD TOXICITY; CESAREAN SECTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; REGRESSION ANALYSIS; RISK ASSESSMENT; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; CESAREAN SECTION; CHEMOPREVENTION; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LOGISTIC MODELS; MALE; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 0034524873     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200012220-00012     Document Type: Article

References (41)

1. Maßnahmen zur Senkung des maternofetalen HIV-Transmissionsrisikos
2. Mode of delivery and gestational age influcence perinatal HIV-1 transmission
3. Potential risk factors for vertical HIV1 transmission in Catalonia, Spain: The protective role of Cesarean section
4. Caesarean section and risk of vertical transmission of HIV-1 infection
5. Mode of delivery and vertical transmission of HIV-I: A review of prospective studies
6. A randomised trial of mode of delivery in women infected with the human immunodeficiency virus
7. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: A randomised clinical trial
8. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus Type 1
9. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
10. Perinatal HIV-1 transmission. Interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort
11. Prevention of vertical HIV transmission: Additive protective effect of elective cesarean section and zidovudine prophylaxis
12. Influence of cesarean section before parturition and antiretroviral prophylaxis on the materno-fetal transmission of HIV
13. Therapeutic and other interventions to reduce the risk of mother-to-child transmission of HIV-1 in Europe
14. Timing of maternal-infant HIV transmission: Associations between intrapartum factors and early polymerase chain reaction results
15. Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire
16. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov Model
17. The sensitivity of HIV-1 DNA-polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission
18. Mechanisms and timing of mother-to-child transmission of HIV-1
19. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV-transmission - Thailand, 1996-1998
20. Short course oral zidovudine for prevention of mother-to-child transmission of HV-1 in Abidjan, Côte d'Ivoire: A randomised trial
21. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: A double-blind placebo-controlled multicentre trial
22. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus
23. Report of the NIH Panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
24. HIV-therapie in der schwangerschaft
25. Recommendations for the management of HIV-infected women and their infants - A European consensus
26. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age
27. Wachstum und reifung
28. A 'bloodless cesarean section' and perinatal transmission of the human immunodeficiency virus
29. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
30. Transport of viruses through fetal membranes: An in vitro model of perinatal transmission
31. The Italian trial on mode of delivery in HIV-positive woman study group: Caesarean section and antiretroviral treatment
32. Complications after caesaren section in HIV-infected women not taking antiretroviral treatment
33. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine
34. Maternal viral load and vertical transmission of HIV-1: An important factor but not the only one
35. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study
36. Decreased CD8 cell-mediated viral suppression and other immunological characteristics of women who transmit human immunodeficiency virus to their infants
37. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission
38. Effects of perinatal zidovudine on hematopoiesis: A comparison of effects on progenitors from human fetuses versus mothers
39. Growth in the first two years of uninfected children born to HIV-1 seropositive mothers
40. The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076)
41. Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy